Clinical Diagnostics Market Report 2026

The clinical diagnostics market size has grown strongly in recent years. It will grow from $81.74 billion in 2025 to $87.7 billion in 2026 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to expansion of diagnostic laboratory networks, increasing disease screening programs, rising prevalence of infectious and chronic diseases, improvements in imaging technologies, growing utilization of lab-based testing.

The clinical diagnostics market size is expected to see strong growth in the next few years. It will grow to $115.39 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to increasing adoption of precision diagnostics, rising investments in advanced imaging systems, expansion of home-based diagnostic testing, growing demand for rapid diagnostic accuracy, increased integration of ai in diagnostics. Major trends in the forecast period include increasing adoption of molecular and genetic diagnostics, rising demand for rapid point-of-care testing, growing integration of imaging and laboratory diagnostics, expansion of automated diagnostic platforms, enhanced focus on early disease detection.

The rising incidence of chronic diseases is expected to drive the growth of the clinical diagnostics market in the coming years. Chronic diseases are long-term conditions that are generally manageable but not curable, often requiring continuous medical care and limiting daily activities. The increasing prevalence of chronic diseases is largely driven by factors such as unhealthy lifestyles, socioeconomic inequalities, and aging populations, which together heighten the risk of conditions including cardiovascular diseases, diabetes, and cancer. Clinical diagnostics play a critical role in managing chronic diseases by enabling accurate diagnosis, monitoring disease progression, guiding treatment decisions, detecting complications at an early stage, supporting personalized medicine, assessing risk factors, and facilitating patient education and self-management. For instance, in April 2025, according to the Centers for Disease Control and Prevention, a US-based federal agency, approximately 194 million adults in the United States, representing 76.4% of the population, reported having at least one chronic condition in 2023. The prevalence was 59.5% among young adults, 78.4% among middle-aged adults, and 93% among older adults. Therefore, the increasing burden of chronic diseases is contributing to the growth of the clinical diagnostics market.

Major companies operating in the clinical diagnostics market are concentrating on the development of innovative technologies, such as advanced liquid biopsy assays, to support comprehensive genomic profiling of solid tumors. A liquid biopsy assay is a minimally invasive diagnostic test that analyzes blood samples to identify cancer-related biomarkers, including circulating tumor cells and circulating tumor DNA, providing valuable insights for diagnosis, treatment monitoring, and personalized care. For example, in November 2023, Illumina Inc., a US-based biotechnology company, launched TruSight Oncology 500 ctDNA v2, an advanced liquid biopsy assay designed to enable detailed genomic profiling of solid tumors. This assay allows precise detection of genetic mutations and alterations, offering in-depth insight into the molecular characteristics of tumors. It enhances the ability to monitor tumor behavior over time and adjust treatment strategies accordingly, thereby improving personalized cancer care. The assay is designed to deliver fast and reliable results, supporting timely clinical decision-making and advancing cancer diagnostics.

In December 2024, Metropolis Healthcare Ltd., an India-based diagnostic services provider, acquired a 100% stake in Core Diagnostics for $0.03 billion (₹247 crore). This acquisition is intended to strengthen Metropolis Healthcare’s presence in the high-end specialized diagnostics segment, expand its capabilities in advanced molecular and genomic testing, and enhance its portfolio of premium diagnostic solutions across India. Core Diagnostics is an India-based specialty diagnostics company that provides high-end clinical testing services in areas such as genomics, oncology, and infectious disease diagnostics.

Major companies operating in the clinical diagnostics market are Siemens Healthineers, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, FUJIFILM Corporation, Becton, Dickinson and Company, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Grifols S.A., Sonic Healthcare Limited, Hologic Inc., Illumina Inc., PerkinElmer Inc., bioMérieux S.A., Sysmex Corporation, Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., Ortho Clinical Diagnostics, BioReference Laboratories Inc., NeoGenomics Laboratories Inc.

North America was the largest region in the clinical diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the clinical diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the clinical diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the clinical diagnostics market by increasing costs of imported imaging systems, laboratory instruments, reagents, and consumables used across diagnostic workflows. Hospitals and diagnostic laboratories in North America and Europe are most affected due to reliance on imported high-value diagnostic equipment, while Asia-Pacific faces cost pressures on reagent supply chains. These tariffs are increasing capital expenditure and test pricing. However, they are also encouraging domestic production of diagnostic reagents, regional equipment assembly, and innovation in cost-efficient diagnostic technologies.

The clinical diagnostics market research report is one of a series of new reports that provides clinical diagnostics market statistics, including clinical diagnostics industry global market size, regional shares, competitors with a clinical diagnostics market share, detailed clinical diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the clinical diagnostics industry. This clinical diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Clinical diagnostics involves the identification, diagnosis, and monitoring of diseases or medical conditions through laboratory testing, imaging methods, and other diagnostic techniques. It includes the analysis and interpretation of patient samples, medical histories, and clinical data to deliver accurate and timely insights that support disease diagnosis, treatment decisions, and ongoing patient management.

The primary tests used in clinical diagnostics include laboratory tests, imaging tests, and others. Laboratory tests are diagnostic procedures conducted on samples such as blood, urine, or tissue to detect diseases, monitor health status, or evaluate treatment effectiveness. The associated products include instruments, reagents, and related items, which are utilized by various end users such as hospital laboratories, diagnostic laboratories, point-of-care testing facilities, and other healthcare settings.

The clinical diagnostics market includes revenues earned by entities by providing services such as genetic testing, molecular diagnostics, pathology services, microbiology testing, and immunology testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The clinical diagnostics market also includes the sale of imaging devices, laboratory analyzers, point-of-care testing devices, endoscopy equipment, and respiratory diagnostic devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.